Teriparatide
C Berg, K Neumeyer, P Kirkpatrick - Nature Reviews. Drug Discovery, 2003 - nature.com
C Berg, K Neumeyer, P Kirkpatrick
Nature Reviews. Drug Discovery, 2003•nature.comAbstract Teriparatide (Forteo; Eli Lilly), a recombinant form of the 34 amino-terminal amino
acids of human parathyroid hormone, was approved by the US FDA in November 2002 for
the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just
reduce bone loss, what impact is it likely to have on the osteoporosis drug market?
acids of human parathyroid hormone, was approved by the US FDA in November 2002 for
the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just
reduce bone loss, what impact is it likely to have on the osteoporosis drug market?
Abstract
Teriparatide (Forteo; Eli Lilly), a recombinant form of the 34 amino-terminal amino acids of human parathyroid hormone, was approved by the US FDA in November 2002 for the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just reduce bone loss, what impact is it likely to have on the osteoporosis drug market?
nature.com